glp-1 agonist therapy information platforms Market Overview: Agonists and the Obesity Market | Blog GLP-1 therapies are changing obesity

The review found that serious anesthesia risks linked to these drugs are uncommon for most patients and can usually be managed through individualized planning rather than stopping the medication

ClinicalTrials.gov (2013)

289 The rise in cAMP activates PKA, a versatile protein kinase that phosphorylates various target proteins

In addition, rising public awareness about weight management and cardiometabolic health is fueling further demand

Going back to the IEL cells for a moment, in Crohns disease and ulcerative colitis (UC) these cells can start to attack the gut lining itself, this further creates a cytotoxic environment, which can further exacerbate IELs to produce pro-inflammatory proteins, this can lead to a compromised intestinal lining, along with alterations in the gut microbiome